Skip to main content

Adagene Inc.

corporate_fare Company Profile

Adagene Inc.

ADAG·NASDAQ·Life Sciences·CIK 0001818838

Adagene Inc. is a clinical-stage biotechnology company focused on researching, developing, and producing monoclonal antibody drugs for cancers in the People's Republic of China. The company's lead product candidate is ADG126, a masked fully-human anti-CTLA-4 mAb, which is in phase 1b/2 clinical development for cancer treatment. Adagene also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, currently in phase 1b/2 clinical trials for advanced/metastatic solid tumors. Other product candidates include ADG206, in phase 1 clinical development for advanced metastatic solid tumors; ADG104, an anti-PD-L1 monoclonal antibody in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb in Phase 2 clinical development. Additionally, the company is developing ADG138, a HER2xCD3 POWERbody in preclinical trials for low expressing tumors and resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody in preclinical trials for off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody in preclinical trials for hematologic and solid tumors; and CD28 T-cell engagers, which are anti-CD28 bispecific POWERbody TCEs for solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Adagene Inc. (NASDAQ:ADAG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for ADAG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ADAG spans 6-K, SCHEDULE 13D/A, 424B5, 20-F.

Recent high-impact activity:

  • Adagene, City of Hope Launch Phase 1 Muzastotug/Ivonescimab Trial in MSS Colorectal Cancer
  • Adagene Completes Phase 2 Enrollment, Triggering $8M Sanofi Second Closing
  • Adagene Completes 60-Patient Enrollment in Randomized Phase 2 Muzastotug/KEYTRUDA Colorectal Trial
  • Adagene Secures NMPA Clearance to Launch Phase 1 Trial for ADG138, a Double-Masked HER2xCD3 T-Cell Engager
  • NMPA Clears Adagene's IND for ADG138, a Double-Masked HER2xCD3 T-Cell Engager

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$7.67M
Net Income
-$17.61M
Diluted EPS
-$0.30
Op. Cash Flow
-$15.66M
Free Cash Flow
-$15.67M
Operating Income
-$21.44M
Cash & Equivalents
$74.52M
Total Debt
$1.85M
Debt / Equity
0.05×
Net Margin
-229.6%
Shares Outstanding
59.23M sh
Source: 20-F · filed 2026-04-01 · accession 0001104659-26-038612

Short Interest & Short Volume

11.83 days to cover

FINRA reported short interest of 2,174,270 shares in ADAG as of the October 30, 2026 settlement, a 2.7% increase from the prior period — about 11.8 days to cover at its recent average daily volume. On November 20, 2026, 30.3% of ADAG volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,174,270 shares as of October 30, 2026
Change vs prior period▲ 2.7%
Days to cover11.83 at avg daily volume of 183,738
Daily short volume (FINRA facilities)30.3% of 272,044 shares on November 20, 2026
5-day average short volume28.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

ADAG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$2.01
52-week range · as of 2026-11-17 $1.42 – $4.85
Market cap
$134.96M
Volume
1.4M (3.2× avg)
3-mo avg 430.7K
Live data · 2026-11-21 04:05 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ADAG - Latest Insights

ADAG
Nov 17, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $2.01 info
Change: +$0.410 (+26%) info
Market Cap: $134.958M info
ADAG
Nov 09, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $2.01 info
Change: +$0.0100 (+0.50%) info
Market Cap: $134.958M info
ADAG
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $2.01 info
Change: +$0.0100 (+0.50%) info
Market Cap: $134.958M info
ADAG
Sep 22, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.21
Real-time Price: $2.01 info
Change: -$1.20 (-37%) info
Market Cap: $134.958M info
ADAG
Sep 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.21
Real-time Price: $2.01 info
Change: -$1.20 (-37%) info
Market Cap: $134.958M info
ADAG
Aug 12, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $2.01 info
Change: -$1.79 (-47%) info
Market Cap: $134.958M info
ADAG
Aug 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $2.01 info
Change: -$1.79 (-47%) info
Market Cap: $134.958M info
ADAG
Jul 06, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.70
Real-time Price: $2.01 info
Change: -$2.69 (-57%) info
Market Cap: $134.958M info
ADAG
Jun 08, 2026, 6:23 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $3.47
Real-time Price: $2.01 info
Change: -$1.46 (-42%) info
Market Cap: $134.958M info
ADAG
Apr 17, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.96
Real-time Price: $2.01 info
Change: -$1.95 (-49%) info
Market Cap: $134.958M info
ADAG
Apr 02, 2026, 4:25 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.99
Real-time Price: $2.01 info
Change: -$1.98 (-50%) info
Market Cap: $134.958M info
ADAG
Apr 02, 2026, 7:11 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.90
Real-time Price: $2.01 info
Change: -$1.89 (-48%) info
Market Cap: $134.958M info
ADAG
Apr 02, 2026, 7:01 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $4.43
Real-time Price: $2.01 info
Change: -$2.42 (-55%) info
Market Cap: $134.958M info
ADAG
Apr 02, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.43
Real-time Price: $2.01 info
Change: -$2.42 (-55%) info
Market Cap: $134.958M info
ADAG
Apr 02, 2026, 6:59 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.43
Real-time Price: $2.01 info
Change: -$2.42 (-55%) info
Market Cap: $134.958M info
ADAG
Apr 01, 2026, 5:15 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $4.76
Real-time Price: $2.01 info
Change: -$2.75 (-58%) info
Market Cap: $134.958M info
ADAG
Apr 01, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.76
Real-time Price: $2.01 info
Change: -$2.75 (-58%) info
Market Cap: $134.958M info
ADAG
Jan 23, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $2.01 info
Change: +$0.270 (+16%) info
Market Cap: $134.958M info
ADAG
Jan 09, 2026, 4:34 PM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $2.01 info
Change: +$0.510 (+34%) info
Market Cap: $134.958M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets